| Literature DB >> 35206510 |
Mihaela Ileana Ionescu1,2, Dan Ștefan Neagoe2, Alexandra Marioara Crăciun1, Oana Teodora Moldovan3,4.
Abstract
The opportunistic infections with Gram-negative bacilli are frequently reported. The clinical studies are focused on the course of human infectious and very often the source of infection remain unclear. We aim to see if the Gram-negative bacilli isolated from a non-contaminated environment-the caves-are reported in human infections. Eleven samples were collected from six Romanian caves. We used the standard procedure used in our clinical laboratory for bacterial identification and for antibiotic susceptibility testing of the cave isolates. Out of the 14 bacterial strains, three isolates are Gram-negative bacilli-one isolate belong to Hafnia alvei and two strains belong to Sphingomonas paucimobilis. We screened for the published studies-full-text original articles or review articles-that reported human infections with S. paucimobilis and H. alvei. Data sources-PubMed and Cochrane library. We retrieved 447 cases from 49 references-262 cases (58.61%) are S. paucimobilis infections and 185 cases (41.39%) are H. alvei infections. The types of infections are diverse but there are some infections more frequent; there are 116 cases (44.27%) and many infections of the bloodstream with S. paucimobilius (116 cases) and 121 cases (65.41%) are urinary tract infections with H. alvei. The acquired source of the bloodstream infections is reported for 93 of S. paucimobilis bloodstream infections-50 cases (43%) are hospital-acquired, and 40 cases (37%) are community-acquired. Most of the infections are reported in patients with different underlying conditions. There are 80 cases (17.9%) are reported of previously healthy persons. Out of the 72 cases of pediatric infections, 62 cases (86.11%) are caused by S. paucimobilis. There are ten death casualties-three are H. alvei infections, and seven are S. paucimobilis infections.Entities:
Keywords: Hafnia alvei; Sphingomonas paucimobilis; bloodstream infections; cave environment; colistin resistance; identification methods; innate antibiotic resistance; opportunistic infections; pediatric infections; urinary tract infections
Mesh:
Year: 2022 PMID: 35206510 PMCID: PMC8872274 DOI: 10.3390/ijerph19042324
Source DB: PubMed Journal: Int J Environ Res Public Health ISSN: 1660-4601 Impact factor: 3.390
Figure 1Flowchart of references selection.
The bacterial strains were isolated from cave samples.
| Sample Code | Cave | Bacterial Strain | Probability (%) * |
|---|---|---|---|
| PTDF1 | Topolniţa |
| 88 |
| PLDF1 | Apă din Valea Leșului |
| 89 |
| PFDF5 | Ferice |
| 90 |
| PFDF3 | Ferice |
| 85 |
| PCDF1 | Cloşani |
|
|
| 92 | |||
| PTSDF2 | Tăuşoare |
|
|
| 90 | |||
| PMDF11 | Muierilor |
| 91 |
| PMDF11A | Muierilor |
| 88 |
| PMDF11B | Muierilor |
| 86 |
| PMOS1 | Muierilor |
|
|
| 97 | |||
| PMOS2 | Muierilor |
| 95 |
* According to Vitek2 identification.
The antibiotic resistance phenotype of the S. paucimobilis and H. alvei strains.
| Antibiotic | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| MIC 1 | CLSI 2 | EUCAST 8 | MIC | CLSI 2 | EUCAST 8 | MIC | CLSI | EUCAST 8 | |
| Ticarcillin | 32 | I | <=8 | S | S | <=8 | - | S 5 | |
| Ticarcillin/Clavulanic Acid | 16 | S | S | <=8 | - | S | <=8 | S | S |
| Piperacillin | 32 | I 6 | I | <=4 | S | S | <=4 | S | S |
| Piperacillin/Tazobactam | 16 | S | S | <=4 | S | S | 8 | S | S |
| Ceftazidime | >=64 | R | R | 2 | S | S | 32 | R 7 | R |
| Cefepime | >=64 | R | R | <=1 | S | S | <=1 | S | S |
| Aztreonam | >=64 | - | (-) | 16 | - | I | 8 | R | |
| Imipenem | 1 | S | S | 1 | S | 0.5 | S | S | |
| Meropenem | <=0.25 | S | S | 0.5 | S | 4 | R | I | |
| Amikacin | <=2 | S | S | <=2 | S | <=2 | S | S | |
| Gentamicin | <=1 | S | IE 3 | <=1 | IE 3 | <=1 | S | S | |
| Tobramycin | <=1 | S | S | <=1 | S | <=1 | S | S | |
| Ciprofloxacin | <=0.25 | S | I | 2 | R | <=0.25 | S | S | |
| Pefloxcin | - | - | - | - | - | - | - | - | - |
| Minocycline | <=1 | S | S | <=1 | S | 8 | I | - | |
| Colistin 4 | >=16 | R | R 9 | 8 | R | R 9 | >=16 | R | R 9 |
| Rifampicin | - | - | - | - | - | - | - | - | - |
| Trimethoprim/Sulfamethoxazole | <=20 | S | S | <=20 | S | <=20 | S | S | |
1 MIC (minimal inhibitory concentration); 2 the interpretation according to CLSI guideline for the category “Other Non-Enterobacterales” with the exception of Colistin that was categorized according to CLSI guideline for Acinetobacter baumanii; 3 IE (Insufficient Evidence that the species is a good target for therapy); 4 Note: increase of breakpoint from 2 to 4 mg/L is already approved (see: Colistin Breakpoints—guidance document 2021); 5 S (Susceptible); 6 I (Intermediate or Susceptible, increased exposure according to the new EUCAST definition); 7 R (Resistant), 8 according to MIC Interpretation Guideline of EUCAST for the non-fermentative Gram-negative Acinetobacter baumanii; 9 the EUCAST interpretation is for polymixin B.
Figure 2The number of the references (study types) included in the present review.
Figure 3The number of case reports/infections with S. paucimobilis and H. alvei retrieved from the 49 references included in the present review. The duplicated were excluded.
The overall comparison of the infections with S. paucimobilis and H. alvei.
| Type of Infections ( | ||
|---|---|---|
| BSI | 116 (44.27) | 20 (10.81) |
| UTI | 4 (1.52) | 121 (65.41) |
| respiratory tract infections | 17 (6.49) | 11 (5.94) |
| bone or soft-tissue infections | 18 (6.87) | 7 (3.78) |
| Intra-abdominal infections | 15 (5.72) | 25 (13.51) |
| Head and neck infections | 20 (7.63) | 0 |
| Ocular infections | 17 (6.49) | 0 |
| Cardiovascular infections | 3 (1.15) | 0 |
| Other types of infections | 52 (19.85) | 1 (0.54) |
Figure 4The number of cases with lethal outcomes of S. paucimobilis and H. alvei infections.
Figure 5The source of infection is associated with bloodstream infections. Standard deviation s. S. paucimobilis s = 15.67; H. alvei s = 3.08.
Figure 6The comparison of the pediatric S. paucimobilis and H. alvei infections according to age.
The acquired source of BSIs.
| The Acquired Source ( | SP | HA |
|---|---|---|
| n (%) | ||
| Hospital 50 (36.76) | 50 (43.10) | - |
| Community 43 (31.62) | 43 (37.06) | - |
| Not specified * 43 (31.62) | 23 (19.82) | 20 (100) |
SP (S. paucimobilis); HA (H. alvei); * included the cases when not clearly specified the acquired source.
The underlying conditions of the patients with BSIs.
| The Underlying Conditions ( | SP | HA |
|---|---|---|
| malignancy 45 (33.08) | 44 (37.93) | 1 (5) |
| diabetes mellitus 15 (11.02) | 15 (12.93) | - |
| bacteremia associated with contaminated iv fentanyl 6 (4.41) | 6 (5.17) | - |
| kidney transplant 6 (4.41) | - | 6 (30) |
| prematurity 5 (3.67) | 4 (3.44) | 1 ** (5) |
| surgery 3 (2.21) | 3 (2.59) | - |
| 2 (1.72) | - | |
| end-stage renal disease 3 (2.21) | 3 (2.59) | |
| HIV 2 (1.47) | 1 (0.86) | 1 (5) |
| neonatal sepsis 2 (1.47) | 2 (1.72) | - |
| burn injury 2 (1.47) | 2 (1.72) | - |
| chronic obstructive pulmonary disease and steroid use 1 (0.74) | 1 (0.86) | - |
| chronic steroid use 1 (0.74) | 1 (0.86) | - |
| chylothorax 1 (0.74) | 1 (0.86) | - |
| Down syndrome 1 (0.74) | 1 (0.86) | - |
| duodenal atresia 1 (0.74) | 1 (0.86) | - |
| epilepsy 1 (0.74) | 1 (0.86) | - |
| imperforate anus 1 (0.74) | 1 (0.86) | - |
| liver cirrhosis and alcoholism 1 (0.74) | 1 (0.86) | - |
| liver transplantation 1 (0.74) | - | 1 (5) |
| perforated appendicitis 1 (0.74) | 1 (0.86) | - |
| pulmonary embolization and atrial fibrillation 1 (0.74) | 1 (0.86) | - |
| septic arthritis 1 (0.74) | 1 (0.86) | - |
| urethral stone 1 (0.74) | 1 (0.86) | - |
| unclear 9 (6.62) | 3 (2.59) | 6 (30) |
| No* 23 (16.91) | 19 (16.38) | 4 (20) |
SP (S. paucimobilis); HA (H. alvei) *; No means—no underlying conditions reported; ** prematurity with necrotizing enterocolitis perforation.
The overall comparison of the pediatric infections with S. paucimobilis and H. alvei according to age.
| Age Range | ||
|---|---|---|
| 0 day to 1 month | 11 (17.19) | 2 (20) |
| 1 month to 1 year | 10 (15.63) | 2 (20) |
| 1 to 3 years | 6 (9.38) | 1 (10) |
| 3 to 6 years | 11 (17.19) | 1 (10) |
| 6 to 12 years | 14 (21.88) | 3 (30) |
| 12 to 18 years | 10 (16.12) | 1 (10) |
The comparisons of the type of pediatric infections with adult infections.
| Type of Infections ( | Pediatric ( | Adult ( | ||
|---|---|---|---|---|
| SP | HA | SP | HA | |
|
|
|
|
|
|
| primary bacteremia 69 (15.44) | 34 (54.83) | 4 (40) | 25 (12.5) | 6 (3.43) |
| CR-BSI 19 (4.25) | 7 (11.29) | 0 | 12 (6) | 0 |
| bacteremia associated with contaminated iv fentanyl 6 (1.34) | 0 | 0 | 6 (3) | 0 |
| urosepsis 10 (2.24) | 3 (4.83) | 1 (10) | 0 | 6 (3.43) |
| pneumonia 4 (0.89) | 1 (1.61) | 0 | 3 (1.5) | 0 |
| meningitis 2 (0.45) | 0 | 1 (10) | 1 (0.5) | 0 |
| bone or soft tissue infections 5 (1.12) | 0 | 0 | 5 (2.5) | 0 |
| intra-abdominal infections * 6 (1.34) | 1 (1.61) | 2 (20) | 3 (1.5) | 0 |
| unspecified 15 (3.35) | 9 (14.52) | 0 | 6 (3) | 0 |
|
|
|
|
|
|
|
|
|
|
|
|
| ventilator-associated pneumonia 1(0.22) | 0 | 0 | 0 | 1 (0.57) |
| empyema 1(0.22) | 0 | 0 | 1 (0.5) | 0 |
| airway inflammation 1(0.22) | 1 (1.61) | 0 | 0 | 0 |
| unspecified 25 (5.6) | 0 | 0 | 15 (7.5) | 10 (5.71) |
|
|
|
|
|
|
| cellulitis 2 (0.45) | 0 | 0 | 2 (1) | 0 |
| otomastoiditis 1 (0.22) | 1 (1.61) | 0 | 0 | 0 |
| osteomyelitis and septic arthritis 1 (0.22) | 1 (1.61) | 0 | 0 | 0 |
| septic arthritis 1 (0.22) | 0 | 0 | 1 (0.5) | 0 |
| osteomyelitis 2 (0.45) | 0 | 0 | 2 (1) | 0 |
| deep infection, open fracture 1(0.22) | 0 | 1 | 0 | 0 |
| focal myositis 1(0.22) | 0 | 0 | 1 (0.5) | 0 |
| necrotizing fasciitis 1(0.22) | 0 | 0 | 0 | 1 (0.57) |
| unspecified soft tissue infections 15(3.36) | 0 | 0 | 10 (5) | 5 (2.86) |
|
|
|
|
|
|
| peritoneal dialysis-associated peritonitis 14 (3.13) | 1 (1.61) | 0 | 13 (6.5) | 0 |
| diarrhea 19 (4.25) | 0 | 1 (10) | 0 | 18 (10.29) |
| cholecystitis 1(0.22) | 0 | 0 | 0 | 1 (0.57) |
| intra-abdominal abscess and peritoneal dialysis related peritonitis 1 (0.22) | 0 | 0 | 1 (0.5) | 0 |
| unspecified 5 (1.12) | 0 | 0 | 0 | 5 (2.86) |
|
|
|
|
|
|
| brain abscess 1 (0.22) | 1 (1.61) | 0 | 0 | 0 |
| cervical adenitis 1 (0.22) | 1 (1.61) | 0 | 0 | 0 |
| central nervous system infections 6 (1.34) | 1 (1.61) | 0 | 5 (2.5) | 0 |
| unspecified 12 (2.68) | 0 | 0 | 12 (6) | 0 |
|
|
|
|
|
|
| endophthalmitis 3 (0.67) | 0 | 0 | 3 (1.5) | 0 |
| neurotrophic keratitis 1 (0.22) | 0 | 0 | 1 (0.5) | 0 |
| ocular contaminations 13 (2.9) | 0 | 0 | 13 (6.5) | 0 |
|
|
|
|
|
|
| cardiac implantable electronic device infection 1 (0.22) | 0 | 0 | 1 (0.5) | 0 |
| endocarditis 1 (0.22) | 0 | 0 | 1 (0.5) | 0 |
| acute phlebitis 1(0.22) | 0 | 0 | 1 (0.5) | 0 |
|
|
|
|
|
|
| periodontal disease 51 (11.41) | 0 | 0 | 51 (25.5) | 0 |
| bromhidrosis 1 (0.22) | 0 | 0 | 1 (0.5) | 0 |
| unclear (body fluid) 1 (0.22) | 0 | 0 | 0 | 1 (0.57) |
IV (intravenous); SP (S. paucimobilis); HA (H. alvei); * (pyomyoma, biliary tract infection, necrotizing enterocolitis perforation, liver abscess, food-borne sepsis); BSI (bloodstream infection); UTI (urinary tract infection); CR-BSI (catheter-related bloodstream infection); in bold we marked the infection categories
The comparisons of the underlying conditions associated with the pediatric infections and adult infections.
| Reported Underlying Conditions ( | Pediatric ( | Adult ( | ||
|---|---|---|---|---|
| SP | HA | SP | HA | |
| Malignancy 50 (11.19) | 22 (35.48) | 1 (10) | 27 (13.5) | 0 |
| Chronic heart disease 8 (1.78) | 0 | 0 | 8 (4) | 0 |
| Chronic renal disease 25 (5.59) | 2 (3.22) | 0 | 16 (8) | 7 (4) |
| Chronic liver disease 5 (1.12) | 0 | 1 (10) | 4 (2) | 0 |
| Chronic pulmonary disease 7 (1.57) | 0 | 0 | 7 (3.5) | 0 |
| Congenital malformation 2 (0.45) | 2 (3.22) | 0 | 0 | 0 |
| Genetic disorders 3 (0.67) | 2 (3.22) | 0 | 1(0.5) | 0 |
| Diabetes mellitus 15 (3.36) | 0 | 0 | 15 (7.5) | 0 |
| Surgery 4 (0.89) | 0 | 0 | 3 (1.5) | 1 (0.57) |
| Trauma 7 (1.57) | 1 (1.61) | 1 (10) | 5 (2.5) | 0 |
| Prematurity * 6 (1.34) | 5 (8.06) | 1 (10) | 0 | 0 |
| Multiple conditions ** 8 (1.79) | 0 | 0 | 8 (4) | 0 |
| other infections 11 (2.46) | 4 (6.45) | 1 (10) | 5 (2.5) | 1 (0.57) |
| Other conditions 16 (3.58) | 1(1.61) | 0 | 15 (7.5) | 0 |
| Chronic steroid use or alcohol abuse *** 10 (2.24) | 0 | 0 | 10 (5) | 0 |
| No underlying conditions reported 80 (17.9) | 22 (35.48) | 5 (50) | 1(0.5) | 52 (29.71) |
| Unclear or not specify 190 (42.51) | 1(1.61) | 0 | 75 (37.5) | 114 (65.14) |
SP (S. paucimobilis); HA (H. alvei); * one H. alvei prematurity with necrotizing enterocolitis perforation; ** there is one case of diabetes mellitus, liver cirrhosis, end-stage renal disease, hepatocellular carcinoma, and one case of diabetes mellitus, colonic tuberculosis, end-stage renal disease mentioned at “Multiple conditions” category; *** there are one case of HIV and drug abuse, one case of malignancy and chronic steroid use, one case of chronic pulmonary disease and steroid use, and one case of chronic liver disease, and alcoholism mentioned at “other infections”, “malignancy”, “chronic pulmonary disease”, “chronic liver disease” category, respectively.
Figure 7The comparison of health-control groups with the S. paucimobilis small airway disease (Eckrick et al.) and H. alvei diarrhea (Ridell et al.), respectively.
Figure 8The bacteriological diagnostic was reported on the 49 references included in the study. (a) Identification methods; (b) antimicrobial susceptibility testing. NS—not specified, Phoenix BD-PAMS—BD Phoenix Automated Microbiology System and gas-liquid chromatography, GLC—gas-liquid chromatography; CBT- conventional biochemical tests.